학술논문

Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.
Document Type
article
Author
Mia M GaudetKaroline B KuchenbaeckerJoseph VijaiRobert J KleinTomas KirchhoffLesley McGuffogDaniel BarrowdaleAlison M DunningAndrew LeeJoe DennisSue HealeyEd DicksPenny SoucyOlga M SinilnikovaVernon S PankratzXianshu WangRonald C EldridgeDaniel C TessierDaniel VincentFrancois BacotFrans B L HogervorstSusan PeockDominique Stoppa-LyonnetKConFab InvestigatorsPaolo PeterlongoRita K SchmutzlerKatherine L NathansonMarion PiedmonteChristian F SingerMads ThomassenOntario Cancer Genetics NetworkThomas v O HansenSusan L NeuhausenIgnacio BlancoMark H GreeneJudith GarberJeffrey N WeitzelIrene L AndrulisDavid E GoldgarEmma D'AndreaTrinidad CaldesHeli NevanlinnaAna OsorioElizabeth J van RensburgAdalgeir ArasonGad RennertAns M W van den OuwelandAnnemarie H van der HoutCarolien M KetsCora M AalfsJuul T WijnenMargreet G E M AusemsHEBONEMBRACEDebra FrostSteve EllisElena FinebergRadka PlatteD Gareth EvansChris JacobsJulian AdlardMarc TischkowitzMary E PorteousFrancesca DamiolaGEMO Study CollaboratorsLisa GolmardLaure BarjhouxMichel LongyMuriel BelottiSandra Fert FerrerSylvie MazoyerAmanda B SpurdleSiranoush ManoukianMonica BarileMaurizio GenuardiNorbert ArnoldAlfons MeindlChristian SutterBarbara WappenschmidtSusan M DomchekGeorg PfeilerEitan FriedmanUffe Birk JensenMark RobsonSohela ShahConxi LazaroPhuong L MaiJavier BenitezMelissa C SoutheyMarjanka K SchmidtPeter A FaschingJulian PetoManjeet K HumphreysQin WangKyriaki MichailidouElinor J SawyerBarbara BurwinkelPascal GuénelStig E BojesenRoger L MilneHermann BrennerMagdalena LochmannGENICA NetworkKristiina AittomäkiThilo DörkSara MargolinArto MannermaaDiether LambrechtsJenny Chang-ClaudePaolo RadiceGraham G GilesChristopher A HaimanRobert WinqvistPeter DevilleeMontserrat García-ClosasNils SchoofMaartje J HooningAngela CoxPaul D P PharoahAnna JakubowskaNick OrrAnna González-NeiraGuillermo PitaM Rosario AlonsoPer HallFergus J CouchJacques SimardDavid AltshulerDouglas F EastonGeorgia Chenevix-TrenchAntonis C AntoniouKenneth Offit
Source
PLoS Genetics, Vol 9, Iss 3, p e1003173 (2013)
Subject
Genetics
QH426-470
Language
English
ISSN
1553-7390
1553-7404
Abstract
Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80-0.90, P = 3.9 × 10(-8)). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.